Glenmark - a Mumbai based pharmaceutical company has received approvals to manufacture and market Favipiravir in India for mild to moderate COVID-19 cases. It is a prescription based medicine.
The company has received the approval from Drugs Controller General of India. So the Glenmark Pharmaceuticals has launched the antiviral drug Fevipiravir under the brand name called FabiFlu. This medicine is launched for the treatment of patients with mild to moderate COVID-19 symptoms. The tablet is priced at Rs. 103 and is prescription based. The drug is available as a 200 mg tablet at an MRP of Rs. 3,500 for a strip of 34 tablets.
The company has received the approval from Drugs Controller General of India. So the Glenmark Pharmaceuticals has launched the antiviral drug Fevipiravir under the brand name called FabiFlu. This medicine is launched for the treatment of patients with mild to moderate COVID-19 symptoms. The tablet is priced at Rs. 103 and is prescription based. The drug is available as a 200 mg tablet at an MRP of Rs. 3,500 for a strip of 34 tablets.
Some information about the new COVID-19 Drug :
- The recommended dose of Favipiravir is 1,800 mg twice a day on first day followed by 800 mg twice daily upto day 14. The drug is available only on prescription.
- The drug is available both through hospitals and the retail channel
- Dr. Rommel Tickoo, Associate Director, Internal medicine, Max Healthcare, said that the drug would be a potential game changer. Clear information about the efficacy of the drug will be available in next two months. The preliminary report is promising.
- Glenmark is producing the active pharmaceutical ingredients ( API ) for the drug at their Ankaleswar plant while the formulation is being manufactured at its Baddi plant.
- The drug can be used for Corona Virus patients with co-morbid conditions such as diabetes and heart disease with mild to moderate COVID_19 symptoms.
For more details about the COVID-19 medicine from Glenmark please click here.
No comments:
Post a Comment